What is the recommended use and dosage of Amiodarone for treating life-threatening arrhythmias?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amiodarone for Life-Threatening Arrhythmias: Dosage and Use Recommendations

For life-threatening arrhythmias, amiodarone should be administered as a 150mg IV bolus over 10 minutes, followed by an infusion of 1mg/min for 6 hours, then 0.5mg/min for the next 18 hours, with conversion to oral therapy when possible. 1

IV Administration Protocol

Initial Treatment for Acute Life-Threatening Arrhythmias

  • Initial dose: 150mg IV bolus over 10 minutes
  • May repeat bolus if needed for breakthrough episodes of VF or hemodynamically unstable VT 2
  • First 24 hours: approximately 1000mg total delivered via infusion 2
  • Infusion rates:
    • First 6 hours: 1mg/min (360mg)
    • Next 18 hours: 0.5mg/min (540mg) 1

Important Administration Considerations

  • Must be delivered by volumetric infusion pump 2
  • Preferably administered through a dedicated central venous catheter 2
  • Use an in-line filter during administration 2
  • Concentrations >2mg/mL should only be administered via central venous catheter 2
  • For infusions >2 hours, concentration should not exceed 2mg/mL unless using central venous access 2
  • Infusions >2 hours must be administered in glass or polyolefin bottles containing D5W 2

Oral Therapy Protocol

Standard Loading and Maintenance

  • Loading phase: 800-1600mg/day in divided doses until 10g total has been given 1
  • Alternative loading: 600-800mg/day in divided doses until 10g total 1
  • Maintenance phase: 200-400mg/day 1

Efficacy and Indications

Amiodarone is recommended as first-line therapy for:

  • Life-threatening ventricular arrhythmias 1
  • Sustained ventricular tachyarrhythmias, especially in patients with left ventricular dysfunction 1
  • Atrial fibrillation 1

Amiodarone has demonstrated:

  • Superior efficacy compared to other antiarrhythmics 1
  • Improved survival and reduced hospital admission rates in shock-resistant, out-of-hospital ventricular fibrillation compared to lidocaine 1
  • 65% success rate in maintaining sinus rhythm at 16 months (vs. 37% for sotalol or propafenone) 1

Monitoring Requirements

Due to amiodarone's narrow therapeutic-toxic window, regular monitoring is essential:

  • ECG monitoring for QT prolongation 1
  • Liver function tests every 6 months 1
  • Thyroid function tests every 6 months 1
  • Pulmonary function tests 1
  • Regular ophthalmologic examinations 1

Important Side Effects and Precautions

Common Adverse Effects

  • Pulmonary toxicity (subacute cough, progressive dyspnea, interstitial infiltrates) 1
  • Cardiac effects (bradycardia, AV block, QT prolongation) 1
  • Thyroid dysfunction 1
  • Corneal microdeposits (nearly universal with long-term use) 3
  • Gastrointestinal effects, particularly constipation 3
  • Neurologic effects (tremor, ataxia) 3

Critical Precautions

  • Avoid high concentration/rapid infusion rates which have resulted in hepatocellular necrosis and acute renal failure 2
  • Be vigilant about drug interactions, particularly with:
    • Warfarin (increased anticoagulation effect) 1
    • Digoxin (increased serum levels) 4
    • Other QT-prolonging medications 1
  • Use lowest effective dose to minimize toxicity risk 1
  • Failure to perform regular surveillance can lead to irreversible damage 1

Special Considerations

  • Amiodarone can be used as an adjunct to reduce ICD shock frequency 1
  • Not justified for long-term therapy in minimally symptomatic atrial fibrillation patients on anticoagulation 1
  • May increase LVEF and decrease worsening heart failure in some patients 1

Common Pitfalls to Avoid

  • Using concentrations >3mg/mL in D5W (associated with high incidence of peripheral vein phlebitis) 2
  • Using evacuated glass containers for admixing (incompatibility with container buffer may cause precipitation) 2
  • Failing to account for amiodarone's adsorption to polyvinyl chloride (PVC) tubing 2
  • Inadequate monitoring for toxicity, particularly pulmonary, hepatic, and thyroid effects 1
  • Overlooking potential drug interactions, especially with digoxin and warfarin 1, 4

References

Guideline

Arrhythmia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias.

Journal of the American College of Cardiology, 1983

Research

Adverse reactions during treatment with amiodarone hydrochloride.

British medical journal (Clinical research ed.), 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.